9 research outputs found
Recommended from our members
Case 15-2011: A 19-Year-Old South African Woman with Headache, Fatigue, and Vaginal Discharge
A 19-year-old woman was seen in a clinic at McCord Hospital in Durban, KwaZulu-Natal Province, South Africa (which is affiliated with Massachusetts General Hospital), because of headache, fatigue, and vaginal discharge
HIV Viral Load Testing in the South African Public Health Setting in the Context of Evolving ART Guidelines and Advances in Technology, 2013 - 2022
HIV viral load (VL) testing plays a key role in the clinical management of HIV as a marker of adherence and antiretroviral efficacy. To date, national and international antiretroviral treatment recommendations have evolved to endorse routine VL testing. South Africa (SA) has recommended routine VL testing since 2004. Progressively, the centralised HIV VL program managed by its National Health Laboratory Service (NHLS) has undergone expansive growth. Retrospective de-identified VL data from 2013 to 2022 were evaluated to review program performance. Test volumes increased from 1,961,720 performed in 2013 to 45,334,864 in 2022. The median total in-laboratory turnaround time (TAT) ranged from 94 h (2015) to 51 h (2022). Implementation of two new assays improved median TATs in all laboratories. Samples of VL greater than 1000 copies/mL declined steadily. Despite initial increases, samples of fewer than 50 copies/mL stagnated at about 70% from 2019 and declined to 68% in 2022. Some variations between assays were observed. Overall, the SA VL program is successful. The scale of the VL program, the largest of its kind in the world by some margin, provides lessons for future public health programs dependent on laboratories for patient outcome and program performance monitoring
Uptake of health services among truck drivers in South Africa: analysis of routine data from nine roadside wellness centres
The South African National strategic plan: what does it mean for our health system?
No abstract available
Differential responsiveness of the platelet biomarkers, systemic CD40 ligand, CD62P, and platelet-derived growth factor-BB, to virally-suppressive antiretroviral therapy
Systemic biomarkers of inflammation, including cytokines and chemokines, are potentially
useful in the management of both HIV infection and non-AIDS-defining disorders.
However, relatively little is known about the utility of measurement of circulating
biomarkers of platelet activation as a strategy to monitor the efficacy of combination
antiretroviral therapy (cART), as well as the persistence of systemic inflammation following
virally-suppressive therapy in HIV-infected persons. These issues have been addressed in
the current study to which a cohort consisting of 199 HIV-infected participants was
recruited, 100 of whom were cART-naïve and the remainder cART-treated and virallysuppressed.
Fifteen healthy control participants were included for comparison. The study
focused on the effects of cART on the responsiveness of three biomarkers of platelet
activation, specifically soluble CD40 ligand (sCD40L), sCD62P (P-selectin), and plateletderived
growth factor-BB (PDGF-BB), measured using multiplex suspension bead array
technology. Most prominently sCD40L in particular, as well as sCD62P, were significantly
elevated in the cART-naïve group relative to both the cART-treated and healthy control
groups. However, levels of PDGF-BB were of comparable magnitude in both the cARTnaïve
and –treated groups, and significantly higher than those of the control group.
Although remaining somewhat higher in the virally-suppressed group relative to healthy
control participants, these findings identify sCD40L, in particular, as a potential biomarker
of successful cART, while PDGF-BB may be indicative of persistent low-level antigenemia.A National Health Laboratory Service Development Grant; the Bill and Melinda Gates Foundation; the South African Department of Health; South African Medical Research Council and the National Research Foundation of South Africa.http://www.frontiersin.org/Immunologyam2022Immunolog
Slow and steady but not related to HIV stigma: physical activity in South Africans living with HIV and chronic pain
HIV stigma may influence physical activity in people living with HIV (PLWH) and chronic pain. We prospectively examined the relationship between stigma, activity and chronic pain in a convenience sample of PLWH initiating antiretroviral therapy in an inner-city clinic in Johannesburg, South Africa. Participants wore accelerometers to measure daily duration and intensity of activity for 2 weeks. Stigma was assessed with the Revised HIV Stigma Scale. Participants [n=81, 89% female, age mean (SD) 42 (8)] were active for a median of 7 h daily (IQR 5.2, 9.2), but at very low intensity, equivalent to a slow walk [median (IQR): 0.39 m s−1 (0.33, 0.50)]. Duration and intensity of activity was not associated with stigma, even after controlling for age, self-assessed wealth, pain intensity and willingness to engage in physical activity (p-values>0.05). As stigma did not associate with greater activity, drivers of sustained activity in South African PLWH remain unclear